Professor Dame Sarah Gilbert
Old Road Research Campus Building, Headington, Oxford, OX3 7DQ
Said Professorship of Vaccinology (DBE)
- Dame Commander of the Most Excellent Order of the British Empire (DBE), for services to Science and Public Health
Professor Gilbert joined the Nuffield Department of Medicine at Oxford University in 1994 and became part of the Jenner Institute (within NDM) when it was founded in 2005. Her chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses. She leads work on influenza vaccine development as well as vaccines for many different emerging pathogens, including Nipah virus, MERS, and Lassa virus.
Professor Gilbert’s work also focuses on the rapid transfer of vaccines into GMP manufacturing and first in human trials. This is achieved through collaboration with colleagues in the Clinical Biomanufacturing Facility and Centre for Clinical Vaccinology and Tropical Medicine, all situated on the Old Road Campus in Oxford.
In 2020 Professor Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus SARS-CoV-2. This vaccine, tested by the University of Oxford in clinical trials of over 23,000 people in the UK, Brazil and South Africa, is now in use in many countries around the world in the fight against the Covid-19 Pandemic.
‘I have worked in the development of vaccines against infectious pathogens for many years and in the last 2 years have been able to draw on all that I have learned in order to respond to the SARS-CoV-2 pandemic. I have been so fortunate to work with a very talented and dedicated team who made it possible to develop a vaccine in less time than anyone thought possible.’
Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.
Cable J. et al, (2022), Annals of the New York Academy of Sciences
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in
under cGMP conditions
Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
van Doremalen N. et al, (2022), Nature Communications, 13
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Alharbi NK. et al, (2022), Vaccines, 10
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Folegatti PM. et al, (2022), Vaccine, 40, 5248 - 5262
list of public engagement